Analytical Data
-
Gene name
DNASE1
- Application
-
Alternative Names
DNaseI; DNL1; DRNI; DNase-I; Dornase alfa
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P24855
-
Expression Region
Gly19~Ala259
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DNASE1, or deoxyribonuclease I, is a critical enzyme involved in DNA fragmentation and is essential for various biological processes, including apoptosis, immune response, and the elimination of extracellular DNA in the context of inflammation and tissue repair. Research into recombinant DNASE1 has gained momentum due to its therapeutic potential, particularly in conditions characterized by excessive extracellular DNA, such as cystic fibrosis and acute respiratory distress syndrome (ARDS). The enzymatic activity of DNASE1 helps in reducing the viscosity of mucus by degrading extracellular DNA, thus improving patient outcomes. Moreover, recombinant DNASE1 is outpacing other treatments in terms of specificity and efficacy, making it a valuable tool in clinical settings. Ongoing studies are focused on enhancing the stability, activity, and delivery mechanisms of DNASE1, alongside understanding its role in various pathophysiological conditions. Advancements in recombinant DNA technology have enabled researchers to produce large quantities of active DNASE1, which is vital for both basic research and therapeutic applications. Overall, the exploration of DNASE1 as a recombinant protein holds promise for novel therapeutic strategies aimed at managing diseases linked to aberrant DNA accumulation, providing a clearer understanding of its mechanisms and potential clinical benefits.
